Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemiaLinde Dekker, Stefan Nierkens, Marc Bierings et al.|Blood Advances|2022Cited by 89
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trialRick Admiraal, Jaap Jan Boelens, Stefan Nierkens et al.|The Lancet Haematology|2022Cited by 71
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Haematologica|2024Cited by 18
Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 3
Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 2